Table S1.
Underlying mechanism of sirtuins in NSCLC in the previous reports
| Study | Sirtuins | Mechanisms |
|---|---|---|
| Xie et al47 | SIRT1 | SIRT1 promote lung tumor growth through downregulation of DLL4/Notch signaling and deacetylation of N1IC |
| Zhang et al29 | SIRT1 | High SIRT1 was associated with chemotherapy resistance |
| Han et al54 | SIRT1 | SIRT1 promotes cell migration |
| Zhu et al48 | SIRT1 | SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27 |
| Grbesa et al30 | SIRT1 | Downregulation of SIRT1 decreased cell proliferation |
| Cheng et al55 | SIRT1 | K-Ras promotes the survival of non–small cell lung cancer cells by cooperating with sirtuin 1 and p27 under ROS stimulation |
| Lu et al49 | SIRT1 | SIRT1 is involved in Benzo[a]pyrene B[a]P-induced transformation associated with activation of the TNF-α/β-catenin axis |
| Li et al44 | SIRT2 | SIRT2 inhibits cell proliferation, induces apoptosis and cell-cycle arrest by increasing the ROS production and p27 levels, and is associated with increased chemotherapy sensitivity |
| Grbesa et al30 | SIRT2 | Downregulation of SIRT2 decreased cell proliferation |
| Xu et al51 | SIRT2 | SIRT2 inhibits cell proliferation and tumor growth via downregulating JMJD2A |
| Li et al36 | SIRT2 | Downregulation of SIRT2 increases the level of SKP2 acetylation, then increases p27 ubiquitination, and finally enhances tumor cell proliferation |
| Luo et al56 | SIRT2 | SPOP promotes SIRT2 degradation and suppresses non–small cell lung cancer cell growth |
| Xiao et al57 | SIRT3 | SIRT3 increased the bax/bcl-2 and bad/bcl-x/L ratios, and promoted AIF translocation to the nucleus. SIRT3 overexpression upregulated p53 and p21 protein levels, and decreased intracellular ROS levels |
| Li et al52 | SIRT3 | Low expression of SIRT3 significantly inhibited mitotic entry, growth, and proliferation of NSCLC cell lines and promoted apoptosis, which was related to energy metabolism involved in the interaction between SIRT3 and NMNAT2 |
| Xiong et al38 | SIRT3 | SIRT3 increases Akt activation by post-transcriptional modification and, then, promotes NSCLC malignancy |
| Xiong et al58 | SIRT3 | SIRT3 deacetylates and promotes degradation of P53 in PTENdefective non–small cell lung cancer |
| Lu et al39 | SIRT5 | SIRT5 promotes cell proliferation and chemotherapy resistance by induction of Nrf2 expression |
| Azuma et al40 | SIRT6 | SIRT6 increases NFkappaB and Beclin1, and is associated with chemotherapy resistance |
| Han et al53 | SIRT6 | SIRT6 suppresses cell proliferation through inhibition of Twist1 expression |
| Kim and Juhnn59 | SIRT6 | Cyclic AMP signaling reduces SIRT6 expression in non–small cell lung cancer cells by promoting ubiquitin-proteasomal degradation via inhibition of the Raf–MEK–ERK pathway |
| Bai et al41 | SIRT6 | SIRT6 increases tumor migration and invasion via increasing ERK1/2 phosphorylation and MMP9 expression |
Abbreviations: SIRT1, sirtuin 1; SIRT2, sirtuin 2; SIRT3, sirtuin 3; SIRT4, sirtuin 4; SIRT5, sirtuin 5; SIRT6, sirtuin 6; SIRT7, sirtuin 7; NSCLC, non-small cell lung cancer; DLL4, Delta-like ligand 4; N1IC, Notch1 intracellular domain; JMJD2A, lysine demethylase 4A; Skp2, S-phase kinase associated protein 2; SPOP, speckle type BTB/POZ protein; BAX, Bcl-2 associated X; BAD, Bcl-2 associated agonist of cell death; Bcl-x/L, Bcl-2 like 1; AIF, apoptosis inducing factor; NMNAT2, nicotinamide nucleotide adenylyltransferase 2; PTEN, phosphatase and tensin homolog; Nrf2, nuclear factor erythroid 2 like 2; Twist1, twist family bHLH transcription factor 1; MMP9, matrix metallopeptidase 9.